ArticleGastroenterology2009
Rare birds in North America: acute hepatitis C cohorts.
Open access · bronzeAbstract readEditorial
In one paragraph
Article in Gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 54 citations in OpenAlex.
- Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Trial
- A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users.Hepatology (Baltimore, Md.) · 2013Trial
- Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C.PLoS pathogens · 2013Trial
- Coordinated expansion of memory T follicular helper and B cells mediates spontaneous clearance of HCV reinfection.Frontiers in immunology · 2024Article
- In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?World journal of hepatology · 2021Review
- Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial.Viruses · 2021Review
- Adaptive Immune Response against Hepatitis C Virus.International journal of molecular sciences · 2020Review
- Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus.Hepatology (Baltimore, Md.) · 2020Article
- Challenges and Promise of a Hepatitis C Virus Vaccine.Cold Spring Harbor perspectives in medicine · 2020Review
- Approaches, Progress, and Challenges to Hepatitis C Vaccine Development.Gastroenterology · 2019Review
- Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance.PLoS pathogens · 2018Article
- IFN-λ3 polymorphism indirectly influences NK cell phenotype and function during acute HCV infection.Immunity, inflammation and disease · 2016Article
- Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection.The Journal of infectious diseases · 2016Article
- Underascertainment of acute hepatitis C virus infections in the U.S. surveillance system: a case series and chart review.Annals of internal medicine · 2015Article
- NK cell function and receptor diversity in the context of HCV infection.Frontiers in microbiology · 2015Review
- Will there be a vaccine to prevent HCV infection?Seminars in liver disease · 2014Review
- Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study.International journal of epidemiology · 2013Article
- IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test.Immunogenetics · 2013Article
- Evolution of CD8+ T cell responses after acute PARV4 infection.Journal of virology · 2013Article
- Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
13 authors.
Andrea L Cox
Kimberly Page
Julie Bruneau
Naglaa H Shoukry
Georg M Lauer
Arthur Y Kim
Hugo R Rosen
Hank Radziewicz
Arash Grakoui
Daniel S Fierer
Andrea D Branch
David E Kaplan
Kyong-Mi Chang
Funding
ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI WALDERS, NATALIE · 1985 to 2008
$52.6MZDV VS ZDV + DDL VS ZDV + DDL + NVP IN ASYMPTOMATIC HIV PATIENTSM01RR000040 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 1985 to 2006
$21.1MAcute Hepatitis C Infection in Young InjectorsR01DA016017 · NIDA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PAGE, KIMBERLY · 2002 to 2018
$14.0MVirus-Host Interactions in Hepatitis C Virus (HCV) InfectionsU19AI040035 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI THOMAS, DAVID L · 1996 to 2009
$12.0MThe role of NK cells during acute HCV infection and antiviral therapyU19AI066345 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LAUER, GEORG MICHAEL · 2005 to 2014
$8.5MScientific CoreU19AI088791 · NIAID · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 2010 to 2020
$8.2MSuppression of HCV-specific CD4+ T Cells by Core ProteinU19AI066328 · NIAID · UNIVERSITY OF COLORADO DENVER · PI ROSEN, HUGO RAMON · 2005 to 2014
$6.8MTreatment of recently acquired hepatitis C virus infectionR01DA015999 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI DORE, GREGORY JOHN · 2003 to 2014
$3.7MCELLULAR IMMUNITY--OUTCOME HEPATITIS C VIRUS INFECTIONR01AI047519 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CHANG, KYONG-MI · 1999 to 2010
$3.1MCD4+ T Cells in Acute Versus Chronic HCV InfectionR01AI105035 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LAUER, GEORG MICHAEL · 2013 to 2017
$2.3MModulation of HCV Gene ExpressionR01DK066939 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI BRANCH, ANDREA D. · 2004 to 2010
$2.0MImmune Responses in Acute Hepatitis C InfectionR01DK060590 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI ROSEN, HUGO RAMON · 2002 to 2010
$2.0MNCRR NIH HHS M01 RR000040NCRR NIH HHS M01 RR000051NIAID NIH HHS K08 AI072191NIAID NIH HHS K23 AI050449NIAID NIH HHS K23 AI054379NIAID NIH HHS L30 AI075975NIAID NIH HHS R01 AI047519NIAID NIH HHS R01 AI105035NIAID NIH HHS U19 AI066328NIAID NIH HHS U19 AI066345NIAID NIH HHS U19 AI088791NIDA NIH HHS DA016156NIDA NIH HHS K08 DA016535NIDA NIH HHS R01 DA015999NIDA NIH HHS R01 DA016017NIDA NIH HHS R01 DA016156NIDDK NIH HHS DK066939NIDDK NIH HHS R01 DK060590NIDDK NIH HHS R01 DK066939NIDDK NIH HHS R01 DK090317
Abstract
PubMed holds no abstract for this paper.
Indexed as
Acute DiseaseCohort StudiesHepatitis CHIV InfectionsHumansRisk FactorsSubstance Abuse, Intravenous
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.